CSL, an Australian biotechnology company, has secured FDA approval for its innovative HAE treatment, ANDEMBRY, marking a significant breakthrough in the field of hereditary angioedema prophylaxis.
Argenx SE’s approval of its subcutaneous treatment Vyvgart for CIDP has sparked debate over whether it’s a genuine breakthrough or market manipulation.
GE Healthcare has received FDA approval for an updated label on its positron emission tomography imaging agent, Vizamyl, allowing for more accurate and confident diagnoses of Alzheimer’s disease.
Dexcom’s stock price has surged due to the US government’s plans to promote wearable health monitoring systems nationwide, with analysts remaining optimistic about the company’s future prospects.
Veeva Systems has formed a strategic partnership with Grünenthal to streamline regulatory processes and accelerate the delivery of life-saving medicines to patients.
Philips is poised to capitalize on the shifting healthcare landscape, driven by a surge in demand for cutting-edge solutions due to an aging population and technological advancements.
Regeneron Pharmaceuticals has made significant strides with the launch of a donation matching program and FDA approval for Dupixent to treat bullous pemphigoid, solidifying its position as a leader in the pharmaceutical industry.
Gilead Sciences has made significant announcements, including a partnership to develop a novel cancer treatment, solidifying its position as a leader in innovative biopharmaceuticals.
Recordati Industria Chimica e Farmaceutica SpA has secured an exclusive licensing deal with Amarin to commercialize cardiovascular medicine Vazkepa in 59 European countries, marking a significant milestone for the company’s growth.